SPRY ARS Pharmaceuticals Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: SPRY

Price (delayed)

$4.18

Market cap

$415.69M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.18

Enterprise value

$579.13M

?
Relative Growth: Rel. Growth: 27
Relative Strength: Rel. Strength: 3
Relative Valuation: Rel. Valuation: 15
Relative Profitability: Rel. Profitability: 13

ARS Pharmaceuticals is a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect patients from allergic reactions that could lead to anaphylaxis. The Company is commercializing ...

Highlights
SPRY's revenue is up by 18% since the previous quarter and by 4.1% year-on-year
SPRY's gross profit is down by 21% year-on-year but it is up by 14% since the previous quarter
ARS Pharmaceuticals's debt has soared by 133% YoY
ARS Pharmaceuticals's equity has plunged by 93% YoY and by 80% from the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://www.silverbacktx.com
Peers: OLMA OMER VIVS ORIC

Key stats

What are the main financial stats of SPRY

SPRY stock price

How has the ARS Pharmaceuticals stock price performed over time
Intraday
-6.7%
1 week
0.36%
1 month
-24.07%
1 year
-57.95%
YTD
-64.12%
QTD
-47.82%

Financial performance

How have ARS Pharmaceuticals's revenue and profit performed over time
Revenue
$116.93M
Gross profit
$83.45M
Operating income
-$216.27M
Net income
-$215.43M
Gross margin
71.4%
Net margin
-184.2%
ARS Pharmaceuticals's gross margin has decreased by 24% YoY and by 3.6% from the previous quarter
SPRY's gross profit is down by 21% year-on-year but it is up by 14% since the previous quarter
SPRY's revenue is up by 18% since the previous quarter and by 4.1% year-on-year
ARS Pharmaceuticals's operating margin has increased by 10% QoQ

Price vs fundamentals

How does SPRY's price correlate with its fundamentals

Growth

What is ARS Pharmaceuticals's growth rate over time

Valuation

What is ARS Pharmaceuticals stock price valuation
SPRY P/E details
P/E
N/A
P/B
33.18
P/S
3.55
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
4.95
SPRY's EPS is down by 8% since the previous quarter
ARS Pharmaceuticals's equity has plunged by 93% YoY and by 80% from the previous quarter
The price to book (P/B) is 53% higher than the last 4 quarters average of 23.3
The price to sales (P/S) is 100% lower than the 5-year quarterly average of 7078.2 and 57% lower than the last 4 quarters average of 8.9
SPRY's revenue is up by 18% since the previous quarter and by 4.1% year-on-year

Efficiency

How efficient is ARS Pharmaceuticals business performance
SPRY's ROE has plunged by 67% from the previous quarter
The company's return on assets fell by 14% QoQ
SPRY's return on sales is up by 9% since the previous quarter
SPRY's return on invested capital is down by 3.4% since the previous quarter

Dividends

What is SPRY's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for SPRY.

Financial health

How did ARS Pharmaceuticals financials performed over time
ARS Pharmaceuticals's total assets is 5% more than its total liabilities
ARS Pharmaceuticals's total liabilities has surged by 96% YoY and by 4.7% QoQ
ARS Pharmaceuticals's quick ratio has decreased by 46% YoY and by 32% from the previous quarter
ARS Pharmaceuticals's debt has soared by 133% YoY
ARS Pharmaceuticals's equity has plunged by 93% YoY and by 80% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.